AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23701860 — intervention group
Group type: EXPERIMENTAL
Intervention: FREEMAN board
Number of subjects: 13
Study 23701860 — intervention group
Group type: COMPARATOR
Intervention: JAKOBS(®) board
Number of subjects: 13
Study 23701860 — intervention group
Group type: COMPARATOR
Intervention: FLAT surface
Number of subjects: 13
Study 20951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group instructed that pain perception over time will habituate (n=10)
Number of subjects: 37
Study 20951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group instructed that pain will increase (n=9)
Number of subjects: 37
Study 20951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group instructed that pain will remain stable (n=8)
Number of subjects: 37
Study 20951617 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 37
Study 18559367 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 660
Study 18559367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 18559367 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (HIV infected)
Number of subjects: 660
Study 18559367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HIV infected)
Number of subjects: 660
Study 18559367 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (HIV uninfected)
Number of subjects: 660
Study 18559367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HIV uninfected)
Number of subjects: 660
Study 16861079 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching-adhesive-modified EndoRez technique
Number of subjects: 0
Study 16861079 — intervention group
Group type: COMPARATOR
Intervention: EndoRez alone
Number of subjects: 0
Study 16861079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V/EndoRez
Number of subjects: 0
Study 16861079 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl-1 h/EDTA-2min/Clearfil Liner Bond 2V/EndoRez
Number of subjects: 0
Study 14713092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D ultrasound (3-DUS)
Number of subjects: 9
Study 14713092 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 9
Study 10844161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (French maritime pine bark extract), 100 mg x 3/day
Number of subjects: 40
Study 10844161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9070128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic drug delivery system using 5-fluorouracil applied directly to the cervix.
Number of subjects: 104
Study 9070128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 104
Study 8508727 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Cue
Number of subjects: 30
Study 8508727 — intervention group
Group type: COMPARATOR
Intervention: Control (Neutral Cues)
Number of subjects: 30
Study 2878839 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacetin-prostaglandin E2-gel
Number of subjects: 0
Study 2878839 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated group)
Number of subjects: 0
Study 29140138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg b.i.d.)
Number of subjects: 316
Study 29140138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 29140138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 316
Study 29140138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib and COX-2 expression
Number of subjects: 316
Study 27034127 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 58100
Study 27034127 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up
Number of subjects: 58100
Study 26100406 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 172
Study 26100406 — intervention group
Group type: COMPARATOR
Intervention: Array comparative genomic hybridization (aCGH)
Number of subjects: 172
Study 24000376 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive biomarker stratified design
Number of subjects: 0
Study 24000376 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) regression
Number of subjects: 0
Study 24000376 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification and treatment-effect mediation
Number of subjects: 0
Study 21114808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) intervention
Number of subjects: 5023
Study 21114808 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 5023
Study 21114808 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 5023
Study 17638034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment plus routine care
Number of subjects: 489
Study 17638034 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 489
Study 16842664 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) in CAD group
Number of subjects: 120
Study 16842664 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal coronary angiogram), n = 82
Number of subjects: 120
Study 12933772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2562
Study 12933772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2562
Study 12933772 — intervention group
Group type: COMPARATOR
Intervention: Intervention group vs Control group
Number of subjects: 2562
Study 12933772 — intervention group
Group type: EXPERIMENTAL
Intervention: One year after the intervention
Number of subjects: 2562
Study 11027812 — intervention group
Group type: EXPERIMENTAL
Intervention: NYVAC-JEV
Number of subjects: 20
Study 11027812 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-JEV
Number of subjects: 20
Study 11027812 — intervention group
Group type: COMPARATOR
Intervention: Formalin-inactivated JE and placebo vaccines
Number of subjects: 20
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Questionnaire
Number of subjects: 81
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland Disability Questionnaire
Number of subjects: 81
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of the main complaint
Number of subjects: 81
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale for pain
Number of subjects: 81
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size statistics
Number of subjects: 81
Study 8826492 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic curves
Number of subjects: 81
Study 1418912 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonized treatment protocols for all types of acute leukaemias in childhood since January 1992.
Number of subjects: 2000
Study 6488684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiamidine (TIAM)
Number of subjects: 30
Study 6488684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLON)
Number of subjects: 30
Study 30570525 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of ART after home-based testing
Number of subjects: 777
Study 30570525 — intervention group
Group type: COMPARATOR
Intervention: Control group following national guidelines for ART initiation
Number of subjects: 777
Study 28130967 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration by laryngeal mask airway (LMA)
Number of subjects: 48
Study 28130967 — intervention group
Group type: COMPARATOR
Intervention: Surfactant administration by endotracheal tube (ETT)
Number of subjects: 48
Study 28130967 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA group
Number of subjects: 48
Study 28130967 — intervention group
Group type: COMPARATOR
Intervention: LMA group and ETT group
Number of subjects: 48
Study 25976090 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (noninvasive energy therapy) for 15 minutes prior to biopsy procedure
Number of subjects: 73
Study 25976090 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 73
Study 25124490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol 200 mg
Number of subjects: 0
Study 25124490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22076964 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI measurement of retrieval-related hippocampal activity
Number of subjects: 0
Study 19079142 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degree anterior capsule polishing (group 1)
Number of subjects: 60
Study 19079142 — intervention group
Group type: COMPARATOR
Intervention: No anterior capsule polishing (group 2, controls)
Number of subjects: 60
Study 17347283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed HDF
Number of subjects: 10
Study 17347283 — intervention group
Group type: COMPARATOR
Intervention: Mid-dilution HDF
Number of subjects: 10
Study 15893381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO(4)) administered at 150-200 mg/h for 24 hours (n=22)
Number of subjects: 41
Study 15893381 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% administered intravenously (n=19)
Number of subjects: 41
Study 16735185 — intervention group
Group type: EXPERIMENTAL
Intervention: NMS60 (0.1 or 0.2 mmol (Gd)/kg)
Number of subjects: 10
Study 10577561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 236
Study 10577561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 8728676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-knife incision combined with 3 weeks of stenting
Number of subjects: 53
Study 8728676 — intervention group
Group type: COMPARATOR
Intervention: Endostent (newly designed stent for internal reflux-free drainage and subcutaneous fixation)
Number of subjects: 53
Study 8728676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-knife incision with 3 weeks of stenting
Number of subjects: 53
Study 1898743 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslorelin 1 microgram/kg.day
Number of subjects: 29
Study 1898743 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslorelin 2 micrograms/kg.day
Number of subjects: 29
Study 1898743 — intervention group
Group type: COMPARATOR
Intervention: Deslorelin 4 micrograms/kg.day
Number of subjects: 29
Study 6349719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithoracic duct lymphocyte globulin (ATDLG), HLA‐haploidentical marrow, and androgen (regimen ABA)
Number of subjects: 42
Study 6349719 — intervention group
Group type: COMPARATOR
Intervention: Androgen alone (concurrent STANDARD care controls)
Number of subjects: 42
Study 6349719 — intervention group
Group type: COMPARATOR
Intervention: Historical STANDARD care controls
Number of subjects: 42
Study 31843072 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching in the luteal phase before controlled ovarian stimulation
Number of subjects: 304
Study 31843072 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 304
Study 30636757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (MAT) with transducer placed in upper limbs
Number of subjects: 82
Study 30636757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (MAT)
Number of subjects: 82
Study 30636757 — intervention group
Group type: COMPARATOR
Intervention: Control recording
Number of subjects: 82
Study 27247487 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise protocol for treating pain (SPTP)
Number of subjects: 352
Study 27247487 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 352
Study 24965060 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + FDADM (n = 42)
Number of subjects: 80
Study 24965060 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + SDADM (n = 38)
Number of subjects: 80
Study 22236345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/ml bupivacaine infusion at 2 ml/h for 48 hours
Number of subjects: 90
Study 22236345 — intervention group
Group type: COMPARATOR
Intervention: 9.0 mg/ml saline infusion at 2 ml/h for 48 hours
Number of subjects: 90
Study 20456311 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of citalopram administered intravenously
Number of subjects: 20
Study 20456311 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 20
Study 16996485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=1308)
Number of subjects: 1308
Study 16996485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=806)
Number of subjects: 1308
Study 16996485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=566)
Number of subjects: 1308
Study 16996485 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (n=472)
Number of subjects: 1308
Study 16996485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=541)
Number of subjects: 1308
Study 16996485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=405)
Number of subjects: 1308
Study 16253595 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1,200 mg/day)
Number of subjects: 43
Study 12384411 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) alone, 10 mg/m² daily for 6 days
Number of subjects: 257
Study 12384411 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (IDA) + arabinosylcytosine (Ara-C), 12 mg/m² IDA daily for 4 days + 200 mg/m² Ara-C daily for 7 days
Number of subjects: 257
Study 10520387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + 15 mg ephedrine
Number of subjects: 40
Study 10520387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + 20 mg ephedrine
Number of subjects: 40
Study 10520387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + 25 mg ephedrine
Number of subjects: 40
Study 10520387 — intervention group
Group type: COMPARATOR
Intervention: Control (Propofol only)
Number of subjects: 40
Study 7753585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 189
Study 7753585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 7753585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment in undernourished children (Z-score < -1)
Number of subjects: 189
Study 7753585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment in adequately nourished children
Number of subjects: 189
Study 31610936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow respiratory support
Number of subjects: 564
Study 31610936 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 564
Study 31144450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90
Study 31144450 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 90
Study 31144450 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 28030702 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks (n=911)
Number of subjects: 1822
Study 28030702 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks (n=911)
Number of subjects: 1822
Study 28030702 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid every 4 weeks
Number of subjects: 1822
Study 28030702 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks
Number of subjects: 1822
Study 25835508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse navigator intervention
Number of subjects: 251
Study 23128822 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55
Study 23128822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20623144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (aprepitant plus ondansetron plus dexamethasone)
Number of subjects: 2383
Study 20623144 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (ondansetron plus dexamethasone)
Number of subjects: 2383
Study 19104723 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 8
Study 19104723 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day) with ACE inhibitor
Number of subjects: 8
Study 19104723 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan and spironolactone
Number of subjects: 8
Study 19104723 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 16144890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 1829
Study 16144890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study 12224847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 20
Study 12224847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10325901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dose oxygen delivery (PDOD) system
Number of subjects: 14
Study 10325901 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 2 l/min
Number of subjects: 14
Study 10325901 — intervention group
Group type: COMPARATOR
Intervention: Air cylinder
Number of subjects: 14
Study 8758418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic gastroscopy
Number of subjects: 0
Study 8758418 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up in Hp negative chronic gastritis patients
Number of subjects: 0
Study 8758418 — intervention group
Group type: COMPARATOR
Intervention: Follow-up studies in Hp positive patients
Number of subjects: 0
Study 1930353 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine nocte (8 p.m.)
Number of subjects: 10
Study 1930353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6352272 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 45
Study 6352272 — intervention group
Group type: COMPARATOR
Intervention: penbutolol 40 mg
Number of subjects: 45
Study 31109458 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based prompts
Number of subjects: 200
Study 31109458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computer-based prompts)
Number of subjects: 200
Study 29293905 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-based toothpaste and mouth rinse
Number of subjects: 63
Study 29293905 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste and mouth rinse
Number of subjects: 63
Study 29798059 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily for 3 months along with betahistine 12 mg Tid for 48 h during episodes
Number of subjects: 23
Study 29798059 — intervention group
Group type: COMPARATOR
Intervention: Betahistine for 48 h during episodes
Number of subjects: 23
Study 24830937 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl2 5% solution (30 mL, equivalent to 382 mg of magnesium)
Number of subjects: 47
Study 24830937 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (30 mL)
Number of subjects: 47
Study 22591959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue fixation system (mini-sling)
Number of subjects: 80
Study 22591959 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape
Number of subjects: 80
Study 19389329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 43
Study 19389329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18609515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-free dialysate
Number of subjects: 50
Study 18609515 — intervention group
Group type: COMPARATOR
Intervention: Ca-1.25 dialysate
Number of subjects: 50
Study 16195056 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness Intervention (RI)
Number of subjects: 12
Study 16195056 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 12
Study 16195056 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP following RI
Number of subjects: 12
Study 12229133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen i.v. at the end of surgery
Number of subjects: 80
Study 12229133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen i.v. before the start of surgery
Number of subjects: 80
Study 12229133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 80
Study 10599859 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial cue stimulus with congruent gaze direction
Number of subjects: 0
Study 10599859 — intervention group
Group type: COMPARATOR
Intervention: Facial cue stimulus with neutral gaze direction
Number of subjects: 0
Study 10599859 — intervention group
Group type: COMPARATOR
Intervention: Facial cue stimulus with incongruent gaze direction
Number of subjects: 0
Study 10599859 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile view of a head with compatible gaze direction
Number of subjects: 0
Study 10599859 — intervention group
Group type: COMPARATOR
Intervention: Front view of a face with a straight gaze
Number of subjects: 0
Study 9454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (two fractions daily, 1.1 Gy each, total dose of 70 Gy to 77 Gy)
Number of subjects: 52
Study 9454160 — intervention group
Group type: COMPARATOR
Intervention: Conventional irradiation (once a day, 2.2 Gy to a total dose of 70 Gy to 77 Gy)
Number of subjects: 52
Study 9454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 52
Study 9454160 — intervention group
Group type: COMPARATOR
Intervention: Conventional irradiation
Number of subjects: 52
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA) 100 to 150 mg intravenously over 6 to 8 hours
Number of subjects: 386
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: angioplasty
Number of subjects: 386
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: coronary artery bypass grafting
Number of subjects: 386
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: employment status
Number of subjects: 386
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: disability status
Number of subjects: 386